Clinical trials: Oral Stage
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma
- Trial name
- NCT02893917
- Testing
- Cediranib, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
- Trial name
- AEGIS-CKD (NCT02968368)
- Testing
- Ferric maltol
- Where
- 27 sites in United States
- Volunteers
- 167 people
- Sponsor
- Shield Therapeutics
Hepatocellular Carcinoma
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis.
- Trial name
- NCT00790218
- Testing
- CF102
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- Can-Fite BioPharma
Multiple Sclerosis
Oral Cladribine in Early Multiple Sclerosis (MS)
A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome).
- Trial name
- ORACLE MS (NCT00725985)
- Testing
- Cladribine, Rebif® new formulation (RNF)
- Where
- 158 sites in United States, Argentina and 32 more
- Volunteers
- 617 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Asthma, Aspirin-Induced
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD).
- Trial name
- NCT03028350
- Testing
- Ifetroban Oral Capsule
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Cumberland Pharmaceuticals
Safety Issues
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
- Trial name
- NCT03473236
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Advanced Solid Tumors
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients.
- Trial name
- NCT00932126
- Testing
- PF-03758309
- Where
- 3 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Pfizer
Head and Neck Cancer
Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx
RATIONALE: Biological therapies, such as tadalafil, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00843635
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Donald T. Weed
Breast Cancer
MEtronomic TrEatment Option in Advanced bReast cAncer
This is a multi-center, randomized phase II trial that will randomise women with ER-positive, HER2-negative (Human Epidermal Growth factor Receptor 2-negative) metastatic or locally relapsed breast cancer in a ratio of 1:1 to…
- Trial name
- METEORA-II (NCT02954055)
- Testing
- Paclitaxel, Cyclophosphamide, Capecitabine
- Where
- 20 sites in Italy
- Volunteers
- 140 people
- Sponsor
- ETOP IBCSG Partners Foundation
Solid Malignancies
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1.
- Trial name
- 14C (NCT02640755)
- Testing
- [14C]AZD2014, Multiple dose AZD2014, Fulvestrant
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Covid19
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease.
- Trial name
- COPS-2003 (NCT04524663)
- Testing
- Camostat Mesilate, Standard of Care Treatment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Stanford University
Healthy
Drug Interaction Study With Rifampicin and Afatinib
The objective of the current study is to investigate the effect of the P-gp inducer rifampicin on the pharmacokinetics (PK) of afatinib in healthy male volunteers
- Trial name
- NCT01396265
- Testing
- Afatinib, Rifampicin
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasm
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.
- Trial name
- NCT00408434
- Testing
- CS-7017
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Healthy Adult Participants
A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
The purpose of this study is to evaluate the bioequivalence of a single oral administration of a vortioxetine (Lu AA21004) 20 mg tablet in comparison with two of vortioxetine 10 mg tablets in Japanese healthy adult participants.
- Trial name
- NCT03437564
- Testing
- Vortioxetine
- Where
- Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Takeda
Herpes Simplex
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth
The purpose of this study is to test whether long-term treatment with oral acyclovir improves the outcome for infants with herpes simplex virus (HSV) disease of the skin, eyes, and mouth (SEM).
- Trial name
- NCT00031447
- Testing
- Acyclovir
- Where
- 28 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelofibrosis, Polycythemia Vera
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia…
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocytosis
- Trial name
- NCT00509899
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
This randomized phase II trial is studying the side effects and how well giving tipifarnib together with etoposide works in treating older patients with newly diagnosed, previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00602771
- Testing
- tipifarnib, etoposide
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide…
- Trial name
- NCT00853047
- Testing
- Telotristat etiprate, Octreotide LAR Depot
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Lexicon Pharmaceuticals
Metrorrhagia
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
- Trial name
- NCT00307801
- Testing
- Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
- Where
- 36 sites in Australia, Czechia and 8 more
- Volunteers
- 231 people
- Sponsor
- Bayer
Healthy
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
The primary objective of the study is to evaluate whether premedication with 325 mg microcoated aspirin (ASA) tablet or a slow-titration dosing schedule of BG00012 reduces the incidence and severity of flushing and GI events…
- Trial name
- NCT01568112
- Testing
- BG00012 (dimethyl fumarate), ASA
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.